Partners:
The ReAlChem-RI project is part of the Innovate-UK funded project ‘Manufacture of renewable alternative chemicals’. This project involves partners from four mid-size biotech companies:
Green Biologics (Project lead: Dr. Liz Jenkinson):
Green Biologics has been a pioneer in bio-based specialty chemicals since 2003. Our products provide a renewable alternative to conventional petrochemical-based commodities for consumer and industrial applications. With our products, you don’t have to sacrifice performance for safer ingredients. In fact, test results are demonstrating that our renewable specialty chemicals outperform conventional petrochemical commodities in certain applications. These are the ingredients that produce a competitive advantage for our customers. These are the renewable alternatives that are good for people and our planet.
DE is the world leading provider of Hydrodynamic Counter Current Chromatography (HdCCC) technology with our branded range of Spectrum High Performance Counter Current Chromatography (HPCCC) processors. Since the launch of the company as a spin out from Brunel University, UK, the processors have evolved along a series of developments to improve their robustness and usability in a wide range of process applications.These HPCCC innovations and unique engineering developments are protected by international patents.
BioExtractions (Wales):
We provide a contract service to the pharmaceutical, agrochemical, chemical, food industries or any industry that needs to separate key compounds from their base complex mixtures. Using state of the art equipment and processes such as High Performance Counter Current Chromatography (HPCCC), membrane filtration and super critical carbon dioxide, BioExtractions (Wales) Ltd. can isolate and extract the key compounds you need from your starting product.
Keit Spectrometers is a company focused on developing FTIR technology for process monitoring and control applications in manufacturing industries. Keit is backed by prominent technology investment firms Longwall Venture Partners, Angel CoFund, UK Innovation & Science Seed Fund, Wood Family Office and Wren Capital and is an active Industry Partner with the Centre for Process Analytics and Control Technology (CPACT), an EnterprisePlus Member of the Royal Society of Chemistry (RSC), and Industry Member of IBioIC.
Links:
Responsible Innovation in Practice and Egenis:
The Responsible Innovation in Practice theme aims to generate new, empirically grounded sociological perspectives on ideas of responsibility, accountability, and sustainability in the life and health sciences and industrial biotechnology. Researchers in this cluster explore emerging concepts, discourses and principles of responsible innovation, and their translation into actual practices across a variety of innovation contexts.
Based at the University of Exeter in the UK, Egenis is committed to providing research of the highest international standard into the nature, historical precedents, and philosophical, social and scientific implications of developments in contemporary biosciences. Also covering the cognitive, biomedical and agricultural sciences, we are interested all of the life sciences’ socio-political, ethical, as well as epistemic repercussions. We have pioneered new approaches to the understanding of genomics, stem cell science, symbiosis, model organisms, data-intensive research, systems and synthetic biology, heredity, and microbiology.
The ‘Crossing biological membranes’ network at Sheffield is designed to foster collaborations between academia, industry, policy makers and NGOs in order to find new approaches to tackle research challenges, translate research and deliver key benefits in Industrial Biotechnology and Bioenergy.
Our multi-disciplinary network drives new ideas to harness the potential of biological resources for producing and processing materials, biopharmaceuticals, chemicals and energy. We are working to understand the mechanisms by which substances are transported into, within, and out of cell factories, which will lead to the development of enabling technologies that are crucial for the future of almost all cell-based IBBE applications.